Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GLSI-100
- Development stage
- Unknown
- Lead developer
- Greenwich LifeSciences
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Administration
- Intradermal
01
Overview
GLSI-100 is an investigational cancer immunotherapy vaccine designed to prevent recurrence in patients with HER2/neu-positive breast cancer. It consists of a nine amino acid peptide (GP2), derived from the transmembrane domain of the HER2/neu protein (amino acids 654–662), combined with granulocyte-macrophage colony stimulating factor (GM-CSF; sargramostim). The mechanism involves stimulating an immune response—specifically activating CD8+ cytotoxic T lymphocytes—to recognize and destroy HER2/neu-expressing tumor cells. GM-CSF acts as an immunoadjuvant by promoting antigen-presenting cell proliferation and enhancing the immune response to GP2. Clinical trials have shown that GLSI-100 is well-tolerated, with no serious adverse events attributed to treatment, and has demonstrated a significant reduction in metastatic breast cancer recurrence rates compared to standard therapies[1][3][4][5][6].
- Brand names
- GLSI-100GLSI100GLSI 100
- Other names
- HER2/neu peptide vaccineGP2 cancer immunotherapyGP-2 cancer immunotherapyGP 2 cancer immunotherapy
02
Targets
ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on GLSI-100.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GLSI-100.